Copy to clipboard 
RTI Surgical (RTIX) entered into an agreement to acquire Zyga Technology, developer of the SImmetry® Sacroiliac Joint Fusion system.
Zyga’s annual revenue is ~US $4MM. The company has also developed the Glyder® Facet Restoration Device. SImmetry is commercially available, while Glyder is not.
As of 2015, Zyga had raised nearly $50MM in a variety of fundings which in part supported clinical trials. SImmetry is entered in the ongoing EVoluSIon clinical trial; recruitment is terminated in a postmarket study of SImmetry in SI joint fusion and decortication. Zyga completed the GLISSADE clinical study to evaluate the safety of Glyder in participants with facet joint pain; recruitment is suspended for DUET, a U.S. study of Glyder in subjects with lumbar facet pain syndrome.
In 2015, analysts estimated the SI joint treatment market at under $70MM. Today, RTIX leadership cites an estimated $100MM market in the U.S., slated to exceed $200MM by 2024, with SI joint fusion procedures growing 20%.
In September 2017, Highmark expanded positive coverage for minimally invasive sacroiliac joint fusion, including all FDA-cleared instrumentation for this indication including cages or screws, with or without bone graft. Previously, the insurer had only covered SI-BONE’s iFuse Implant System®. Highmark represents the 4th-largest Blue Cross and Blue Shield-affiliated insurer in the U.S.
As of 2015, SI-BONE reportedly claimed 85% of the market with iFuse. Other FDA-cleared SI devices are available from Camber Spine, CoreLink, Globus Medical, Life Spine, Medtronic, SI-BONE, SICAGE, SpineFrontier, X-Spine, etc.
Sources: RTI Surgical, Inc.; zyga.com; clinicaltrials.gov; ORTHOWORLD Inc.
RTI Surgical (RTIX) entered into an agreement to acquire Zyga Technology, developer of the SImmetry® Sacroiliac Joint Fusion system.
Zyga's annual revenue is ~US $4MM. The company has also developed the Glyder® Facet Restoration Device. SImmetry is commercially available, while Glyder is not.
As of 2015, Zyga had raised nearly...
RTI Surgical (RTIX) entered into an agreement to acquire Zyga Technology, developer of the SImmetry® Sacroiliac Joint Fusion system.
Zyga’s annual revenue is ~US $4MM. The company has also developed the Glyder® Facet Restoration Device. SImmetry is commercially available, while Glyder is not.
As of 2015, Zyga had raised nearly $50MM in a variety of fundings which in part supported clinical trials. SImmetry is entered in the ongoing EVoluSIon clinical trial; recruitment is terminated in a postmarket study of SImmetry in SI joint fusion and decortication. Zyga completed the GLISSADE clinical study to evaluate the safety of Glyder in participants with facet joint pain; recruitment is suspended for DUET, a U.S. study of Glyder in subjects with lumbar facet pain syndrome.
In 2015, analysts estimated the SI joint treatment market at under $70MM. Today, RTIX leadership cites an estimated $100MM market in the U.S., slated to exceed $200MM by 2024, with SI joint fusion procedures growing 20%.
In September 2017, Highmark expanded positive coverage for minimally invasive sacroiliac joint fusion, including all FDA-cleared instrumentation for this indication including cages or screws, with or without bone graft. Previously, the insurer had only covered SI-BONE’s iFuse Implant System®. Highmark represents the 4th-largest Blue Cross and Blue Shield-affiliated insurer in the U.S.
As of 2015, SI-BONE reportedly claimed 85% of the market with iFuse. Other FDA-cleared SI devices are available from Camber Spine, CoreLink, Globus Medical, Life Spine, Medtronic, SI-BONE, SICAGE, SpineFrontier, X-Spine, etc.
Sources: RTI Surgical, Inc.; zyga.com; clinicaltrials.gov; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
